Venus Remedies, a prominent global pharmaceutical company, has bolstered its international footprint by obtaining marketing approvals for three drugs in the Philippines and Saudi Arabia, underscoring its commitment to advancing global healthcare solutions, the company received regulatory approval from the Philippines, the second-largest market in the Association of Southeast Asian Nations (ASEAN), for the chemotherapy drug paclitaxel and zoledronic acid, a medication used in treating metabolic bone disorders

Venus Remedies, a prominent global pharmaceutical company, has bolstered its international footprint by obtaining marketing approvals for three drugs in the Philippines and Saudi Arabia.

Underscoring its commitment to advancing global healthcare solutions, the company received regulatory approval from the Philippines, the second-largest market in the Association of Southeast Asian Nations (ASEAN), for the chemotherapy drug paclitaxel and zoledronic acid, a medication used in treating metabolic bone disorders.

Additionally, Venus Remedies secured a permit for marketing from Saudi Arabia, the largest pharmaceutical market in the Gulf Cooperation Council (GCC), for the oncology drug bleomycin.

The Philippines, expected to witness significant pharmaceutical market growth, reaching $4.917 billion by 2026, represents a key market for Venus Remedies. Similarly, the pharmaceutical market in Saudi Arabia is projected to grow to $7.19 billion by 2028, with a five-year compound annual growth rate (CAGR) of 5.85 per cent.

As one of the leading exporters of paclitaxel from India, Venus Remedies supplies the drug to numerous countries, including Colombia, Thailand, Tanzania, Morocco, Myanmar, Indonesia, Saudi Arabia, Malaysia, Zimbabwe, Sri Lanka, Pakistan, Kenya, and Botswana. The company also exports zoledronic acid to various nations, such as the Dominican Republic, Vietnam, Colombia, Jamaica, Tanzania, Zimbabwe, and Kenya. Moreover, bleomycin is distributed to countries like Colombia, Saudi Arabia, Zimbabwe, Iraq, Chile, Costa Rica, Myanmar, and Hungary.

Saransh Chaudhary, President of Global Critical Care at Venus Remedies Ltd. and CEO of Venus Medicine Research Centre, said that the marketing permits from the Philippines and Saudi Arabia are significant achievements. He highlighted the company's regulatory prowess and commitment to quality, positioning Venus Remedies as a prominent supplier of these three drugs across 15 countries.

Aditi K. Chaudhary, President of the company’s international business wing, emphasised the strategic importance of these regulatory milestones, considering them crucial steps in the company's international expansion strategy. She expressed pride in contributing to the enhancement of healthcare access and outcomes in Southeast Asia and the Middle East.

Remaining steadfast in its mission to provide innovative and effective pharmaceutical products, Venus Remedies said that it aims to leverage these marketing permits to positively impact patient care and well-being globally.